title: Effectiveness of sotalol treatment in symptomatic Brugada syndrome.
abstract: We describe a 53-year-old man with recurrent syncopal events and a malignant family history who was treated for 13 years with sotalol drug therapy with no further occurrence of Brugada syndrome symptoms. Genetic testing revealed that he carried a Brugada syndrome sodium channel SCN5A mutation (4189delT). This finding suggests that sotalol may be of therapeutic benefit in such patients.
authors.affiliation: University of California-San Francisco, San Francisco, CA, USA. kaglatter@ucdavis.edu
authors.forename: Kathryn A
authors.initials: KA
authors.lastname: Glatter
authors.forename: Qing
authors.initials: Q
authors.lastname: Wang
authors.forename: Mark
authors.initials: M
authors.lastname: Keating
authors.forename: Shenghan
authors.initials: S
authors.lastname: Chen
authors.forename: Nipavan
authors.initials: N
authors.lastname: Chiamvimonvat
authors.forename: Melvin M
authors.initials: MM
authors.lastname: Scheinman
mesh_terms: D000328:Adult; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D003937:Diagnosis, Differential; D004562:Electrocardiography; D005260:Female; D020022:Genetic Predisposition to Disease; D006801:Humans; D008297:Male; D008875:Middle Aged; D010375:Pedigree; D013015:Sotalol / Q000627:therapeutic use*; D013577:Syndrome; D014693:Ventricular Fibrillation / Q000175:diagnosis* / Q000188:drug therapy* / Q000235:genetics / Q000503:physiopathology
chemical_list: D000889:Anti-Arrhythmia Agents; D013015:Sotalol